iRhythm (IRTC) Technologies announced that the ... uninterrupted continuous monitoring, LTCM, using a Zio XT patch ECG device, for detecting nonsustained ventricular tachycardia, NSVT, a known ...

Technologies announced that the results of the Extended Ambulatory ECG Monitoring Enhances Identification of Higher-Risk ...

Application error: a client-side exception has occurred (see the browser console for more information).

The Food and Drug Administration cleared prior design modifications for iRhythm Technologies’ Zio AT wearable cardiac monitoring system in the first of two 510(k) submissions to the agency tied ...

iRhythm's stock surged over 20% today after ... We currently offer three Zio System options — the Zio Monitor System, the Zio XT System, and the Zio AT System. The Zio AT System is a ...

iRhythm Technologies has announced that the US Food and Drug Administration (FDA) has cleared design updates made to its Zio AT device. The Zio AI continuous monitoring system combines a wearable ...

iRhythm Technologies, Inc. IRTC has received FDA 510(k) clearance for design changes and enhancements previously made to its Zio AT device. These modifications, submitted via letter to file ...

Quentin Blackford, President and CEO of iRhythm, stated, "This clearance is related to modifications and certain enhancements to our Zio AT device previously made via letter to file and has been a ...

The Zio AT services are provided by iRhythm's independent diagnostic testing facilities located in San Francisco, California, Deerfield, Illinois and Houston, Texas. Zio Services' Clinically ...